Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03695835 · ClinicalTrials.gov registry record
A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.
A clinical trial of Adenocarcinoma, sponsored by Gary Onik MD.
- Completed
- Registry status
- 27
- Enrollment target
- 1
- Study location
NCT03695835 is a study of Adenocarcinoma that has completed, run by Gary Onik MD. The registered enrollment target is 27 participants, below the 95-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03695835, a study of Adenocarcinoma, has completed, sponsored by Gary Onik MD.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospectively monitored through their normal standard of care for their original cancer.
Conditions Studied
Interventions
- DEVICE Ablation
- DRUG Immunotherapeutic Agents
Study Locations (1)
Florida
- The Center for High Risk and Recurrent Prostate Cancer - Fort Lauderdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-04-11 |
| Est. Completion | 2020-06-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03695835
The ClinicalTrials.gov registry entry for NCT03695835 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (72% lower). The listed sponsor is Gary Onik MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Ablation is the first listed.
NCT03695835 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03695835 about?
NCT03695835 is a clinical study titled "A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.". A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospec...
What is the current status of trial NCT03695835?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2018-04-11. Estimated completion is 2020-06-17.
What conditions does trial NCT03695835 study?
This clinical trial studies the following conditions: Adenocarcinoma.
What interventions are being tested in trial NCT03695835?
The interventions under investigation include: Ablation (DEVICE), Immunotherapeutic Agents (DRUG).
Who is sponsoring clinical trial NCT03695835?
This trial is sponsored by Gary Onik MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03695835 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
-
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
RECRUITING · Phase 1
-
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
RECRUITING · Phase 1
-
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.